Corneal microcysts

Dhillon, Virinder K; Faraj, Lana A; El‐Alfy, Mohamed; Bhatt, Uday; Said, Dalia G.; Dua, Harminder S

doi:10.1136/bjophthalmol-2013-303705

Cited by 3 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Corneal epithelial microcysts have been reported as a nonspecific consequence of generalized corneal disease and corneal dystrophies and in association with cytosine arabinoside (Ara-C), a common chemotherapeutic agent. [84][85][86][87][88] Recent confocal microscopic investigation, however, failed to demonstrate true cysts within or under the affected corneal epithelium. 89 Instead, necrotic epithelial foci were observed within the basal layer early, thereafter progressing to involve the apical layers as disease progressed.…”

Section: Discussionmentioning

confidence: 99%

Ocular Adverse Events Associated with Antibody–Drug Conjugates in Human Clinical Trials

Eaton¹,

Miller

Mannis

et al. 2015

Journal of Ocular Pharmacology and Therapeutics

215

193

View full text Add to dashboard Cite

This article reviews ocular adverse events (AEs) reported in association with administration of antibody-drug conjugates (ADCs) in human clinical trials. References reporting ocular toxicity or AEs associated with ADCs were collected using online publication searches. Articles, abstracts, or citations were included if they cited ocular toxicities or vision-impairing AEs with a confirmed or suspected association with ADC administration. Twenty-two references were found citing ocular or vision-impairing AEs in association with ADC administration. All references reported use of ADCs in human clinical trials for treatment of various malignancies. The molecular target and cytotoxic agent varied depending on the ADC used. Ocular AEs affected a diversity of ocular tissues. The most commonly reported AEs involved the ocular surface and included blurred vision, dry eye, and corneal abnormalities (including microcystic corneal disease). Most ocular AEs were not severe (≤ grade 2) or dose limiting. Clinical outcomes were not consistently reported, but when specified, most AEs improved or resolved with cessation of treatment or with ameliorative therapy. A diverse range of ocular AEs are reported in association with administration of ADCs for the treatment of cancer. The toxicologic mechanism(s) and pathogenesis of such events are not well understood, but most are mild in severity and reversible. Drug development and medical professionals should be aware of the clinical features of these events to facilitate early recognition and intervention in the assessment of preclinical development programs and in human clinical trials.

show abstract

Section: Discussionmentioning

confidence: 99%

Ocular Adverse Events Associated with Antibody–Drug Conjugates in Human Clinical Trials

Eaton¹,

Miller

Mannis

et al. 2015

Journal of Ocular Pharmacology and Therapeutics

215

193

View full text Add to dashboard Cite

show abstract

“…3 While there is no standard treatment protocol for cytarabine-induced corneal toxicity, dexamethasone and prednisolone drops have been reported effective in treatment. 1 , 4 , 5 In this report we want to emphasize that loteprednol etabonate, a topical soft steroid, is also as effective as dexamethasone and prednisolone in the treatment of cytarabine-induced corneal toxicity.…”

Section: Introductionmentioning

confidence: 99%

Cytarabine-Induced Corneal Toxicity: Clinical Features and Relief of Symptoms with Loteprednol Etabonate 0.5% in Two Patients

Özcan¹,

Uçakhan²

2021

tjo

View full text Add to dashboard Cite

We report two patients who developed toxic keratopathy following high-dose cytarabine chemotherapy and whose symptoms resolved following topical loteprednol etabonate 0.5% treatment. A 25-year-old woman and a 26-year-old man with acute myeloid leukemia were referred to our department with symptoms of ocular discomfort, photophobia, and blurred vision after consolidation chemotherapy. Central corneal epithelial microcysts were observed bilaterally in both patients, and in vivo confocal microscopy showed highly reflective disseminated granular and irregular intraepithelial opacities, mainly in the basal epithelial layers. Loteprednol etabonate 0.5% relieved both patients’ symptoms in less than a week, and the microcysts disappeared in 2 to 3 weeks of treatment. Although there is no standardized treatment protocol for cytarabine-induced corneal toxicity, dexamethasone 0.1% and prednisolone phosphate 1.0% were reported to be effective in the resolution of discomfort and symptoms. In the two patients we report herein, loteprednol etabonate 0.5% four times daily was also effective in suppressing the symptoms.

show abstract

Cytarabine

2015

Reactions Weekly

View full text Add to dashboard Cite

Corneal microcysts

Cited by 3 publications

References 10 publications

Ocular Adverse Events Associated with Antibody–Drug Conjugates in Human Clinical Trials

Ocular Adverse Events Associated with Antibody–Drug Conjugates in Human Clinical Trials

Cytarabine-Induced Corneal Toxicity: Clinical Features and Relief of Symptoms with Loteprednol Etabonate 0.5% in Two Patients

Cytarabine

Contact Info

Product

Resources

About